Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight
The type 2 diabetes market is expected to witness steady growth, driven by the rising global prevalence of diabetes, increasing rates of obesity and sedentary lifestyles, and growing awareness of early diagnosis and disease management. The expanding use of newer therapies, including GLP-1 receptor agonists, dual and triple incretin-based treatments, SGLT2 inhibitors, and other novel glucose-lowering agents, is further supporting market expansion. Additionally, the launch of emerging therapies such as agriSema (Novo Nordisk), Survodutide (BI 456906; Boehringer Ingelheim), Retatrutide (Eli Lilly), ASC30 (Ascletis Pharma), and others will further drive the market growth upward.
New York, USA, Oct. 05, 2026 (GLOBE NEWSWIRE) — Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight
The type 2 diabetes market is expected to witness steady growth, driven by the rising global prevalence of diabetes, increasing rates of obesity and sedentary lifestyles, and growing awareness of early diagnosis and disease management. The expanding use of newer therapies, including GLP-1 receptor agonists, dual and triple incretin-based treatments, SGLT2 inhibitors, and other novel glucose-lowering agents, is further supporting market expansion. Additionally, the launch of emerging therapies such as agriSema (Novo Nordisk), Survodutide (BI 456906; Boehringer Ingelheim), Retatrutide (Eli Lilly), ASC30 (Ascletis Pharma), and others will further drive the market growth upward.
Recently published Type 2 Diabetes Market Insights report includes a comprehensive understanding of current treatment practices, type 2 diabetes emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Type 2 Diabetes Market Summary
- The total type 2 diabetes treatment market size is expected to grow positively by 2036 in the leading markets.
- The United States accounted for the largest type 2 diabetes treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- Over 38 million Americans, around 1 in 10, have diabetes, with 90% to 95% of cases being type 2 diabetes.
- Key type 2 diabetes companies, including Novo Nordisk, Eli Lilly and Company, Boehringer Ingelheim, Ascletis Pharma, Roche, Alnylam Pharmaceuticals, Innovent Biologics, and others, are actively working on innovative type 2 diabetes drugs.
- Some of the key type 2 diabetes therapies in clinical trials include CagriSema, Survodutide (BI 456906), Retatrutide, ASC30, RG6652 (CT-996), RG6640 (CT-388), RG6849 (petrelintide), ALN-4324, IBI3032, and others. These novel type 2 diabetes therapies are anticipated to enter the type 2 diabetes market in the forecast period and are expected to change the market.
Discover the future of the type 2 diabetes mellitus treatment market @ https://www.delveinsight.com/report-store/type-2-diabetes-market
Key Factors Driving the Growth of the Type 2 Diabetes Market
- Rising Global Prevalence of Type 2 Diabetes: The growing incidence of type 2 diabetes, driven by aging populations, sedentary lifestyles, and unhealthy dietary patterns, is expanding the patient pool and increasing demand for long-term treatment.
- Growing Adoption of GLP-1–Based Therapies: GLP-1 receptor agonists and related incretin-based therapies are gaining traction due to their ability to improve glycemic control while also supporting weight management and offering potential cardiovascular benefits.
- Expansion of Combination Therapies: The use of fixed-dose combinations and multi-drug treatment strategies is increasing as patients require more intensive glycemic management over the course of disease progression.
- Launch of Emerging T2DM Drugs: The dynamics of the type 2 diabetes market are expected to change in the coming years owing to the launch of emerging therapies such as agriSema (Novo Nordisk), Survodutide (BI 456906; Boehringer Ingelheim), Retatrutide (Eli Lilly), ASC30 (Ascletis Pharma), RG6652 (CT-996), RG6640 (CT-388), and RG6849 (petrelintide) (Roche), ALN-4324 (Alnylam Pharmaceuticals), IBI3032 (Innovent Biologics), and others.
Aparna Thakur, Project Manager of Forecasting at DelveInsight, stated that metformin, SGLT2 inhibitors, and GLP-1 receptor-based therapies remain key pillars of T2DM management, while dual- and multi-target metabolic therapies are driving innovation. The emergence of novel combination therapies and next-generation incretin-based agents is expected to broaden treatment options and potentially reshape the T2DM market by addressing glycemic control, weight management, cardiovascular and renal outcomes, and other persistent unmet needs beyond conventional glucose lowering.
Type 2 Diabetes Market Analysis
- GLP-1 may have a broader cardiometabolic impact beyond glycemic control, as GLP-1 receptor signaling may influence blood pressure regulation and sympathetic nervous system activity.
- This underscores the potential of GLP-1–based therapies to address both blood glucose management and associated cardiovascular risk factors.
- Real-world data indicate a substantial challenge with GLP-1 therapy persistence, with as many as 64% of patients discontinuing treatment within the first year and 74% by the second year. These findings highlight the need for more convenient oral treatment options that may reduce the burden associated with injectable therapies and potentially support longer-term treatment adherence.
- The marketed therapies for T2DM include semaglutide (OZEMPIC, RYBELSUS), liraglutide (VICTOZA), dulaglutide (TRULICITY), tirzepatide (MOUNJARO), empagliflozin (JARDIANCE), dapagliflozin (FARXIGA), canagliflozin (INVOKANA), sitagliptin (JANUVIA), linagliptin (TRADJENTA), and saxagliptin (ONGLYZA).
- These established treatments offer effective glycemic control, while several also provide weight-management, cardiovascular, and renal benefits, reinforcing their role in the evolving T2DM treatment landscape.
- The T2DM GLP-1 pipeline features promising next-generation candidates, including retatrutide (Eli Lilly), CagriSema (Novo Nordisk), and survodutide (Boehringer Ingelheim), among others.
- Through multi-receptor agonism and complementary metabolic mechanisms, these emerging therapies are being developed to deliver improved glycemic control, greater weight-loss efficacy, and broader cardiometabolic benefits, with the potential to address important unmet needs in T2DM management.
Learn more about the intravenous treatment for type 2 diabetes @ Type 2 Diabetes Drugs
Type 2 Diabetes Competitive Landscape
Some of the type 2 diabetes drugs under development include CagriSema (Novo Nordisk), Survodutide (BI 456906; Boehringer Ingelheim), Retatrutide (Eli Lilly), ASC30 (Ascletis Pharma), RG6652 (CT-996), RG6640 (CT-388), and RG6849 (petrelintide) (Roche), ALN-4324 (Alnylam Pharmaceuticals), IBI3032 (Innovent Biologics), and others.
Novo Nordisk’s CagriSema is a once-weekly subcutaneous fixed-dose combination of the long-acting amylin analogue cagrilintide (2.4 mg) and the GLP-1 receptor agonist semaglutide (2.4 mg). The therapy is being investigated in adults with type 2 diabetes mellitus (T2DM), with the potential to improve glycemic control while also supporting weight management and addressing cardiometabolic risk factors.
Boehringer Ingelheim’s Survodutide (BI 456906) is a dual glucagon receptor (GCGR) and GLP-1 receptor agonist under evaluation for the treatment of T2DM. Through its dual-receptor mechanism, survodutide is intended to improve glucose control, promote weight loss, and deliver broader metabolic benefits. The compound is currently being evaluated in Phase III clinical development.
Roche’s CT-996 is a once-daily oral small-molecule GLP-1 receptor agonist under development for the treatment of obesity and type 2 diabetes. Unlike endogenous GLP-1, CT-996 is engineered as a biased agonist that preferentially activates cAMP signaling while inducing minimal to no beta-arrestin recruitment. This differentiated signaling profile is anticipated to provide robust glycemic control, substantial weight reduction, and favorable tolerability.
The anticipated launch of these emerging type 2 diabetes therapies are poised to transform the type 2 diabetes market landscape in the coming years. As these cutting-edge type 2 diabetes therapies continue to mature and gain regulatory approval, they are expected to reshape the type 2 diabetes market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about the advances in type 2 diabetes treatment, visit @ Type 2 Diabetes Medication Market
Recent Developments in the Type 2 Diabetes Market
- In September 2026, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin for use alongside diet and exercise to help control blood glucose levels in adults with type 2 diabetes.
- In August 2026, Eli Lilly reported positive results from three additional Phase III trials evaluating retatrutide in obesity. With these data, the clinical development package is now complete to support global regulatory submissions across obesity, obstructive sleep apnea, and knee osteoarthritis pain. The company plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027.
- In August 2026, Novo Nordisk announced the nationwide launch of Awiqli® (insulin icodec-abae) injection 700 units/mL, the first once-weekly basal insulin approved as an adjunct to diet and exercise to improve glycemic control (blood sugar) in adults living with type 2 diabetes, following the US Food and Drug Administration (FDA) approval earlier this year.
- In August 2026, Structure Therapeutics announced that the first patients have been dosed in the Phase III ACCOMPLISH program, which includes two clinical trials evaluating aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist.
- In July 2026, Kailera Therapeutics, Inc. announced positive topline data from two additional Phase III clinical trials of oral small molecule GLP-1 receptor agonist HRS-7535 (also known as KAI-7535) conducted by Hengrui Pharma.
- In June 2026, Boehringer Ingelheim reported detailed Phase III results from the SYNCHRONIZE-1 and SYNCHRONIZE-MASLD trials, demonstrating that survodutide reduced visceral fat by up to 34% and liver fat by up to 63.1% in people with obesity. The results were presented at the ADA 2026 Scientific Sessions.
- In June 2026, Novo Nordisk reported positive Phase III results from the REIMAGINE 1–3 trials, demonstrating that CagriSema achieved significant reductions in HbA1c and body weight in adults with type 2 diabetes. The findings were presented at the ADA 2026 Scientific Sessions.
Type 2 Diabetes Epidemiology Segmentation
The type 2 diabetes epidemiology section provides insights into the historical and current type 2 diabetes patient pool and forecasted trends for the leading markets. In France, the prevalence of T2DM is 4.6% in the general population, with rates increasing substantially with age. Approximately one in five men aged 70 to 85 years and one in seven women aged 75 to 85 years receive pharmacological treatment for T2DM.
The type 2 diabetes market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:
- Total Prevalent Cases of Type 2 Diabetes Mellitus
- Total Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus
- Age-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus
- Gender-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus
- Treated Cases of Type 2 Diabetes Mellitus
Download the report to understand the type 2 diabetes drug treatment @ Type 2 Diabetes Treatment Options
| Type 2 Diabetes Market Report Metrics | Details |
| Study Period | 2022–2036 |
| Type 2 Diabetes Market Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Type 2 Diabetes Market Epidemiology Segmentation | Total Prevalent Cases of Type 2 Diabetes Mellitus, Total Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus, Age-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus, Gender-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus, and Treated Cases of Type 2 Diabetes Mellitus |
| Key Type 2 Diabetes Companies | Novo Nordisk, Eli Lilly and Company, Boehringer Ingelheim, Ascletis Pharma, Roche, Alnylam Pharmaceuticals, Innovent Biologics, AstraZeneca, and others |
| Key Type 2 Diabetes Therapies | CagriSema, Survodutide (BI 456906), Retatrutide, ASC30, RG6652 (CT-996), RG6640 (CT-388), RG6849 (petrelintide), ALN-4324, IBI3032, OZEMPIC, RYBELSUS, ZEPBOUND, JARDIANCE, FARXIGA, and others |
Scope of the Type 2 Diabetes Market Report
- Type 2 Diabetes Patient Population Forecast
- Type 2 Diabetes Therapeutics Market Size
- Type 2 Diabetes Pipeline Analysis
- Type 2 Diabetes Market Size and Trends
- Type 2 Diabetes Market Opportunity
- Type 2 Diabetes Market Unmet Needs
- KOL’s Views on Type 2 Diabetes
- Type 2 Diabetes Market Access and Reimbursement
Discover more about next-generation type 2 diabetes drugs @ Type 2 Diabetes Clinical Trials
Table of Contents
| 1 | Type 2 Diabetes Market Key Insights |
| 2 | Type 2 Diabetes Market Report Introduction |
| 3 | Executive Summary |
| 4 | Key Events |
| 5 | Epidemiology and Market Forecast Methodology |
| 6 | Type 2 Diabetes Mellitus (T2DM) Market Overview at a Glance |
| 6.1 | Clinical Landscape Analysis (By Phase, Molecule Type, and RoA) |
| 6.2 | Market Share (%) Distribution of T2DM By Therapies in the 7MM, in 2025 |
| 6.3 | Market Share (%) Distribution of T2DM By Therapies in the 7MM, in 2036 |
| 7 | Disease Background and Overview of Type 2 Diabetes Mellitus (T2DM) |
| 7.1 | Introduction |
| 7.2 | Sign and symptoms |
| 7.3 | Risk Factors |
| 7.4 | Subtypes of T2DM |
| 7.5 | Pathophysiology |
| 7.7 | Biomarkers |
| 7.8 | Diagnosis |
| 8 | Treatment and Management |
| 8.1 | Treatment Algorithm |
| 8.2 | Guidelines |
| 9 | Epidemiology and Patient Population of Type 2 Diabetes Mellitus (T2DM) |
| 9.1 | Key Findings |
| 9.2 | Assumptions and Rationale |
| 9.3 | Type 2 Diabetes Mellitus Prevalent Cases in the 7MM |
| 9.4 | The United States |
| 9.4.1 | Total Prevalent Cases of Type 2 Diabetes Mellitus in the United States |
| 9.4.2 | Total Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus in the United States |
| 9.4.3 | Age-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus in the United States |
| 9.4.4 | Gender-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus in the United States |
| 9.4.5 | Treated Cases of Type 2 Diabetes Mellitus in the United States |
| 9.5 | EU4 and the UK |
| 9.6 | Japan |
| 10 | Patient Journey of Type 2 Diabetes Mellitus (T2DM) |
| 11 | Marketed Therapies |
| 11.1 | Competitive landscape of marketed therapies |
| 11.2 | Semaglutide (OZEMPIC/WEGOVY/RYBELSUS): Novo Nordisk |
| 11.2.1 | Drug Description |
| 11.2.2 | Regulatory Milestones |
| 11.2.3 | Other Developmental Activities |
| 11.2.4 | Summary of Pivotal Trials |
| 11.2.5 | Clinical Development |
| 11.2.5.1 | Clinical Trial Information |
| 11.2.6 | Analyst’s Views |
| 11.3 | Bexagliflozin (BRENZAVVY): TheracosBio |
| Note: List to be continued in the report | |
| 12 | Emerging Type 2 Diabetes Drugs |
| 12.1 | Competitive landscape of emerging therapies |
| 12.2 | CagriSema: Novo Nordisk |
| 12.2.1 | Drug Description |
| 12.2.2 | Other Developmental Activities |
| 12.2.3 | Clinical Development |
| 12.2.3.1 | Clinical Trials Information |
| 12.2.4 | Analyst’s Views |
| 12.3 | Survodutide (BI 456906): Boehringer Ingelheim |
| Note: List to be continued in the report | |
| 13 | Type 2 Diabetes Mellitus Market: 7MM Analysis |
| 13.1 | Key Findings |
| 13.2 | Market Outlook of T2DM |
| 13.3 | Conjoint Analysis of T2DM |
| 13.4 | Key Type 2 Diabetes Market Forecast Assumptions |
| 13.5 | Total Market Size of T2DM in the 7MM |
| 13.6 | Total Market Size of T2DM by Therapies in the 7MM |
| 13.7 | The United States Type 2 Diabetes Market |
| 13.7.1 | Total Market Size of T2DM in the United States |
| 13.7.2 | Total Market Size of T2DM by Therapies in the United States |
| 13.8 | EU4 and the UK Type 2 Diabetes Market |
| 13.9 | Japan Type 2 Diabetes Market |
| 14 | Unmet Needs of Type 2 Diabetes Mellitus (T2DM) |
| 15 | SWOT Analysis of Type 2 Diabetes Mellitus (T2DM) |
| 16 | KOL Views of Type 2 Diabetes Mellitus (T2DM) |
| 17 | Market Access and Reimbursement of Type 2 Diabetes Mellitus (T2DM) |
| 17.1 | The United States |
| 17.2 | EU4 and the UK |
| 17.3 | Japan |
| 17.4 | Summary and comparison of Market Access and Pricing Policy Developments in 2025 |
| 17.5 | Market Access and Reimbursement of Type 2 Diabetes Mellitus (T2DM) Therapies |
| 18 | Bibliography |
| 19 | Type 2 Diabetes Market Report Methodology |
Related Reports
Type 2 Diabetes Clinical Trial Analysis
Type 2 Diabetes Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key type 2 diabetes companies, including Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., and others.
Diabetes Market
Diabetes Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc., and others.
GLP-1 Agonists Market
GLP-1 Agonists Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key GLP-1 agonists companies, including Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk, Amgen, Viking Therapeutics, Regor Therapeutics, Carmot Therapeutics, Roche, GlaxoSmithKline, Sanofi, and others.
Obesity Market
Obesity Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key obesity companies, including Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, and others.
Diabetes Drugs Market
Diabetes Drugs Market Insights, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes drugs companies, including Novo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca plc, Boehringer Ingelheim, Merck & Co., Inc., Johnson & Johnson, Takeda Pharmaceutical Company, Novartis AG, Biocon Ltd., and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +14699457679
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaEveningPost.com takes no editorial responsibility for the same.